# 1. Financial Performance ## A. Key Figures * **Total Income:** **₹179.2 Cr** Q3 FY'26 (+52%) · **₹482.1 Cr** 9M FY'26 (+38%) * **Revenue ex-NSS:** **₹156 Cr** Q3 FY'26 (+26%) · **₹416 Cr** 9M FY'26 (+21%) * EBITDA: ₹66.8 Cr Q3 FY'26 (+60%) · ₹181.5 Cr 9M FY'26 (+33%) * PAT: ₹47.7 Cr Q3 FY'26 (+66%) · ₹125.7 Cr 9M FY'26 ## B. Revenue Growth * **Strong Top-Line Momentum:** Robust double-digit revenue growth across quarters, driven by increased demand and deeper customer engagement. * **Core Business Resilience:** Underlying revenue (ex-NSS) shows sustained double-digit expansion, indicating healthy organic growth. ## C. EBITDA & Margins * **Margin Pressure in Core:** Despite strong EBITDA growth, 9M margin contraction reflects **unfavorable business mix** and cost dynamics. * **High-Margin Specialty Segment:** Sudeep Pharma sustains **35–37% EBITDA margins**, underpinning profitability in the specialty vertical. * **Battery Business Potential:** New segment poised for **~3x asset turns**, **high ROE/ROCE**, and efficient working capital cycle, signaling scalable returns. ## D. Profit After Tax * **Outsize Earnings Growth:** PAT outpaces revenue and EBITDA growth in Q3, reflecting operating leverage and one-time benefits. ## E. Working Capital * **Extended Cycle Management:** Networking capital days at **~180 days**, consistent with growth investment; granular inventory/receivables data not disclosed. --- # 2. Product & Segment Performance ## A. Key Figures * **Revenue Mix (9M FY'26):** ~43% specialty ingredients · ~57% pharma, food & nutrition * **NSS Quarterly Revenue:** **~₹17 Cr** · Stand-alone growth (ex-NSS): **+35% YoY** * **Pharma Segment (Q4 FY'25):** **₹112 Cr** (vs. prior run rate of ₹70–80 Cr) * **Specialty Ingredients Growth:** Projected **30–35%+** in coming years ## B. Specialty Ingredients * **Strategic Pivot:** Transitioned from mineral excipients to a technology-driven global supplier across 100+ countries, with specialty ingredients now a core growth engine. * **Growth Drivers:** Magnesium and iron portfolios expanding due to health trends; encapsulated and premixed lines driving value and margin uplift. * **Capacity & Margin Focus:** 50% of new capacity dedicated to high-margin, low-competition molecules (e.g., gluconates, glycinates), expected to fuel long-term margin expansion. * **Execution Momentum:** Specialty segment scaled rapidly from <10% (FY'23) to ~40% of revenue, with path to 70–80% capacity utilization in two years. * **Commercial Validation:** Secured supply approval from a leading infant nutrition player for vitamin-mineral blends, signaling near-term revenue ramp. ## C. Pharma, Food & Nutrition * **Battery Materials Breakthrough:** Sudeep Advanced Materials (SAM) is the first ex-China source of battery-grade iron phosphate, capturing early-mover advantage amid global supply chain diversification. * **Technology Leverage:** Decade-long iron phosphate expertise and five years of R&D have enabled competitive electrochemical performance vs. Chinese suppliers. * **Strong Segment Performance:** Pharma, food & nutrition maintained dominant share (~57% in 9M FY'26) with a notable revenue spike in Q4 FY'25. ## D. M&A & Innovation Platforms * **NSS Integration on Track:** Acquisition adds formulation capabilities and regulatory market access; margin parity achieved via supply chain synergies and internal sourcing. * **Sustainable Growth Outlook:** NSS expected to grow at ~15% annually, supported by integration and new leadership appointment. * **Liposomal Platform Expansion:** Indigenous Lipoboost technology enables high-absorption products (e.g., 80% better iron uptake) and expansion into vitamins, DHA, and cosmeceuticals. --- # 3. Geography & Export Mix ## A. Key Figures * **Export Revenue Mix:** **62%** of total revenue (9M FY26 and Q3 FY26) · **Domestic Revenue Mix:** **38%** ## B. India Domestic * **Stable Domestic Growth:** Indian market delivered nearly **20% growth** in the quarter, underpinned by consistent demand and long-standing customer relationships. * **Reliable Base:** Domestic operations continue to serve as a stable and resilient foundation amid expanding global footprint. ## C. North America * **Strategic Partner Positioning:** North America is a core market where Sudeep is increasingly viewed as a strategic partner in resilient, compliant supply chains. * **Seasonal Export Strength:** Q4 typically sees peak performance, driven by export demand in pharma and food nutrition segments. ## D. Europe & APAC * **APAC Momentum:** Asia-Pacific growth fueled by deeper collaboration with leading FMCG and infant nutrition clients, marked by rising repeat orders and broader product adoption. * **Europe Emergence:** Europe shows strong sequential growth as dedicated sales team secures regulatory and customer approvals, positioning it as a meaningful growth market. * **Targeted Market Expansion:** New sales teams in Europe and the US are accelerating regional growth, with product offerings tailored to local therapeutic and regulatory needs. ## E. Emerging Markets * **Global Reach:** Broad-based geographic growth in Q3 across over **100 countries**, reflecting strong underlying demand and early returns from strategic international investments. --- # 4. Capacity & Manufacturing ## A. Key Figures * **Nandesari Greenfield Capacity:** **51,200 MT** (commissioning Mar '26) * **Pharma Greenfield Capacity:** **51,000 MT** (commissioning next month) * **Battery Materials Phase 1 Capacity:** **25,000 TPY** (operational early 2027) * **Total Project Capex:** **₹550–600 Cr** (battery materials) · **₹150 Cr** (Pharma Greenfield, **₹10–15 Cr** remaining) ## B. Greenfield Projects * **Strategic Scale-Up:** Multiple greenfield expansions nearing completion, enabling industrial-scale production of high-value molecules in pharma, food, and nutrition. * **Capital Efficiency:** Green technology drives **50% reduction in capex** (ex-land/utilities), with superior opex efficiency and sustainability across geographies. ## C. Battery Materials Facility * **Phased Expansion Plan:** Battery materials facility on track for early 2027 commissioning, with a scalable pathway from 25,000 to **100,000 tons** based on off-take agreements, potentially skipping intermediate stages. * **Financial Timing:** Revenue and depreciation impacts expected from **FY '28**, with all prior costs capitalized during 18-month construction period. ## D. Utilization Rates * **Current Utilization Divergence:** Pharma, food & nutrition segment runs at **65%-70% utilization**, while specialty ingredients operate at **~40%**, set for ramp-up post-approvals. * **Near-Term Constraints:** New facility ramp-up delayed by **6–12 months of customer approvals**, limiting meaningful contribution to H2 and significant impact to **FY '28**; Greenfield Pharma utilization to remain low in FY '27. ## E. Commissioning Timeline * **Sequential Commissioning:** Core business facility commissioning in **March**, followed by customer qualification; full commercial scale-up expected only from **H2 onward**, aligning with FY '28 financial impact. --- # 5. Customer & Demand Trends ## A. Key Figures * **Customer Engagements:** **34** across battery value chain (70% sample approval rate) * **Regulatory Distinction:** Only **Indian company** with CEP certification for calcium carbonate in Europe; one of **nine globally** ## B. Key Customer Wins * **Strategic Supply Expansion:** Secured supply role with global tortilla leader via shelf-life-extending encapsulated ingredient, displacing U.S. supplier and unlocking **significant volume potential**. * **Deepening Global Partnerships:** World’s largest consumer goods company expands sourcing to Brazil and India, while increasing wallet share in the U.S., reflecting trust in Sudeep’s customized formulations. * **Platform Validation:** Surge in facility visits from global OEMs and battery players underscores growing confidence in Sudeep’s battery materials platform. * **Demand Catalysts:** US trade deal expected to boost project pipeline, market visibility, and customer wallet share, with re-engagement underway with key tortilla manufacturer. ## C. Off-take Engagements * **Advanced Commercial Readiness:** Majority of battery customers have validated iron phosphate samples; multiple off-take agreements under active discussion or finalization, signaling strong medium-term demand visibility. * **Export Momentum:** Q4 revenue growth driven by new international contracts, with call-offs accelerating as customers begin fiscal planning—demand uptick observed even pre-trade deal finalization. ## D. Regulatory Approvals * **Competitive Regulatory Edge:** CEP certification for calcium carbonate provides fast-track access to regulated European markets, serving as a key customer entry enabler. * **Approval Cycle Headwind:** Infant nutrition segment (NSS) faces 12+ month regulatory timelines, constraining near-term growth despite robust pipeline. --- # 6. Pricing & Supply Risks ## A. Key Figures * **Iron Phosphate Price Increase:** **15%-20%** from China (recent weeks) due to VAT rebate reduction ## B. Chinese Cost Shifts * **Structural Cost Advantage:** Green chemistry technology enables lower opex and capex versus Chinese peers, enhancing long-term competitiveness. * **China Policy Tailwinds:** Elimination of VAT rebates in China boosts relative cost position for Indian exporters, especially in **di-calcium phosphate and battery chemicals**. * **Input Cost Pressure:** Rising Chinese iron phosphate prices reflect tightening policy and supply dynamics, reinforcing demand for non-Chinese alternatives. ## C. Tariff Impacts * **Tariff Mitigation Success:** Company passed through tariff impact to **90% of affected US business** with **no margin dilution**, despite initial customer hesitation. * **Export Growth Catalysts:** Reversal of US tariffs and EU free trade agreement expected to accelerate volume growth and expand wallet share in key markets. * **Strategic Tariff Positioning:** India poised to become **one of Asia’s most tariff-competitive nations** for US exports, strengthening Sudeep’s export advantage. ## D. Competitive Positioning * **Differentiated, Not Discounted:** Focus on engineered, customized solutions in high-barrier markets underpins sustainable margins; avoids direct price competition with China. * **Non-Chinese Alternative Narrative:** Positioned as preferred supplier for battery chemicals in regulated markets, supported by **superior iron phosphate product claims** and regulatory alignment. * **Margin Aspirations:** Proprietary technology and process efficiency expected to deliver **higher-than-industry-average EBITDA margins** in battery materials post-launch. --- # 7. Guidance & Outlook ## A. Key Figures * **Capex (Battery Plant):** **₹550–600 Cr** (Phases 1 & beyond) * **Phase 1 Investment:** **₹300 Cr** (incl. land for 100,000-ton facility) * **Asset Turnover Target:** **~3x** (battery materials project) ## B. Growth Sustainability * **Sustained Growth Trajectory:** Management expects current strong momentum—well above prior-year single-digit growth—to continue into next year, supported by portfolio strength and strategic platforms. * **No Formal Guidance, But Stable Outlook:** While no specific revenue guidance is provided, leadership anticipates sustaining recent growth trends with a **stable and similar margin profile**. ## C. Margin Profile * **Margin Resilience Targeted:** Despite new Greenfield capex, company aims to maintain historical margin levels in FY '27 with **no significant margin changes expected**. ## D. Capex Plan * **Self-Funded Expansion:** Battery materials capex primarily financed through internal accruals, with **minimal debt impact** and **no significant near-term interest burden**. ## E. Revenue Timing * **Liposomal Product Revenue Onset:** Commercial contribution expected from **H2 FY27**, with meaningful scale anticipated in **FY28**. * **Battery Materials Revenue Ramp:** First revenues from battery chemicals project forecasted in **FY28**, with no material impact expected in FY '27.